regeneron could be different. it's patton issues, won an important court decision when that very cholesterol drug causing pressure in the stock. finally there is a cycle that sticks out like a sore thumb. health care rock star but the stars are held by endless acquisitions that masked slowing organic growth revealed as subpar without more deals to fuel the business. bottom line, look, it could be worse. these companies could be the two biggest losers but they are not. many like allergan, regeneron are buy or on the verge of being so. you need patience to buy them. "mad money" is back after the break. caca m w(cur >>> it is time, it is time for the first lightning round of 2017. wow, take your calls rapid fire. play the sound and then the lightning round is over. are you ready? time for the lightning round. start with john in louisiana, john? >> hey, james, how are you doing? >> i'm doing good. happy new year. what's shake sng. >> caller: happy new year. i'm finally on the phone with themaniac. it's an honor. i've

. >>> regeneron and sanofi plan to appeal a u.s.ourt ruling banning them from selling their cholesterol drug because it infringes on amgen's patents. a jury found amgen's patents valid last month. regeneron and sanofi could reach a settlement to give amgen royalties on the u.s. sales of drugs. >>> samsung says fourth quarter profit likely rose 50 % to the iest lev highest level in three years. the optimistic outlook comes despite a slight drop in revenues and the expected $2 billion hit. >>> some more stocks to watch. johnson & johnson and actelion have approached the takeover board about the structure of the takeovers. the proposed deal would let johnson & johnson buy actelion for $2.60 a share. it would allow shareholders to benefit financially from the companies research and development pipeline. actelion up a bit in swiss trade. >>> helen of troy's third quarter results beat forecast and they're raising the full-year earnings outlook. however they are cutting revenue guidance on expectation that cold and flu season will be below

remember rememb regeneron and vertex. and regeneron last night lost a patent lawsuit.ee how that stock will trade today. a lot of fear with what happens with donald trump, drug pricing, will there be a drug pricing tweeted during the conference. >> what is amgen's cholesterol drug? >> pks9 inhibitor. >> of course. >> it's for dogs. >> that's right. that's right. for canines. >> it's for dogs? >> it's a canine joke. it's a new target. pks k9. >> i have no idea what's going on. >> oh. stop the presses. >>> coming up, it's been a volatile week for currencies. we'll talk strategy. you've been busy. >> thanks, birthday boy. >> i know. i'm the one starting to slip. you've been busy. you've been busy. you've had some happening. this time you have an excuse. how to prepare your portfolio for the trump administration. here's a quick check of what's happening in the european markets right now. sydney queen. i love that. >>> the dollar >>> the dollar retreating from a 14-year high after weaker labor data. this has been a huge move. we're showing you the dollar index. the move in

regeneron is going to speak, and i want to know what they have to say about the big verdict in amgen's favor in that patent dispute i just mentioned. one suggestion. let's say you want to buy amgen stock. here's an idea. why not wait until you hear what regeneron says about what it will do to try to appeal the delaware court ruling, the one that took its competing drug off the market. maybe that could create a nice buying opportunity in amgen stock on tuesday morning. so don't pull the trigger as soon as amgen talks. jpmorgan's huge. this is a huge conference, and it dominates tuesday too. two major old-line pharma companies, bristol-myers and pfizer, are going to speak. we want to find out if bristol-myers is planning any restructuring around the opdivo anti-cancer franchise after that brug failed to heit some clinicl trial end points. pfizer, there's a lot of chatter they could be breaking up. you know, i've been a big fan of alkermese. i want to know more about its drugs for combating opioid addiction. that is a hot topic under the incoming trump administration. trump cares about th

david, big court case, regeneron vers versus amgen. wins. >> okay. >> this is over this pralien, very important high cholesterol drug a lot of doctors want to start giving to people once they're absolutely sure because this is the one if you have really high cholesterol this could be a lifesaver. >> was the court case about a patent. >> and amgen outright won. now, i can't believe -- there's a lot of people are saying wait a second. does this mean regeneron's just blocked? yes, for now. and goldman takes amgen from 202 to 218. >> wow. >> david -- i know. remember, sanofi's been buying regeneron stock throughout. >> yes. >> but i think this is a clear call to buy amgen. i think people should buy amgen if it's only up five bucks. this could be some sort of settlement, but david, it's stunning. amgen could go higher. >> interesting. amgen, jim, also on a very different front has an enormous amount of overseas cash, maybe the single largest in the industry. >> is that true? >> and certainly when you compare to their cash flow as a percenta

won ahigher because it ruling saying regeneron cannot sell their drugs in u.s. bti earlier higher by about .4% -- wti earlier higher by about .4%. bank of america is the next tory. mark: poised to boost bonuses for many bond traders. -- income america is the next story. joining us now with the latest .s laura keller the rebound in sentiment around fixed income that we experienced in the second half of last year. expectas you can see, we 10% for traders of fixed income products. that is much better than we would have expected the first half of the year when it was really terrible across every credit or currency. mark: not such good times for equity. laura: the disc record -- that is correct. 5% fewer if you are trading equities products. the stock world is not doing as well as fixed income for the end of the year. reward or this a incentive? not much of an incentive for equity traders. laura: this is a bank that is having trouble returning on equity like they wanted. they are trying to cut costs. it is a bit hard to justify these bonuses for these equity traders

. >> when we come back, live today two of the jp morgan health care conference with the ceo of regeneronhen mario gabelli will join scott. the dow up almost 60. >>> welcome back to "squawk alley." let's go back to the jp morgan health conference in san francisco. >> john, thank you so much. we're joined by dr. schriffer. i want to start by talking to you about a pipeline drug that many people think is under valued. >> it is our drug that addresses allergic diseases. they are an epidemic that have been accuracying every year. bad asthma, alert allergies to drugs and all sorts of things. they might impact the diseases, and we think they might be able to do that. we hope the first approval will come at the end of march. monitor to severe top of dermetitus. we want to follow that with hopefully more data on asthma, working on nasal pallups. >> in your presentation, yesterday, you said the industry doesn't office put the patients first. >> we try to live that. members of the national academy of sciences. we're both ph.ds. prices go up so dramatically and make it hard for patients to get acces

sanofi and regeneron say they will appeal a ruling by a u.s. court which banned them from selling their cholesterol drug after the biotech company amgen accused them of patent infringement. amgen saw shares rally on the back of the judgment. the companies could still agree on a settlement. >>> goldman sachs added fiat to its conviction list. it has strong sales data from europe, china and u.s. >>> and the bank of england's chief economist says there may be errors in brexit forecasting. he said economic models failed to take into account irrational behavior. the boe has come under criticism after predicting a dramatic slowdown in the uk economy post brexit vote as data shows the economy remained robust. >>> norway's prime minister said she was fearful that britain was on the path towards a hard brexit. in an interview with reuters, she said the uk lacked the negotiation know how to pull off such a complex eu deal. take a listen. >> they are lacking also the type of experience. so it takes a little longer time to develop what will be the right wa

federal judge ruling sanofi and regeneron refringed the patent they hold for a cholesterol drug.ng lower by 2%. back to you. >> seema mody, thank you. >>> we're about an hour away from trump's highly anticipated intelligence briefing at trump tower. we'll talk to re/code's kara swisher on what tech companies may do, when "squawk alley" comes back. >>> first, two retail names moving in opposite directions. jcpenney, the latest department chain to have lower sales but gap to the upside. dow's up 40 and now just 60 points away from dow 20,000. back in a minute. >>> good morning, everyone. i'm sue herera. here is your "cnbc news update" at this hour. elizabeth warren announcing via e-mail this morning that she is running for re-election in 2018, seeking a second term as senator from massachusetts. she said voters didn't send her to washington to roll over and play dead to donald trump and his team of billionaires and bigots. those are her words. >>> the whale that killed a trainer at seaworld orlando in 2010 has died. tilikum was also profiled in a documentary that helped sway popula

and fundamentals have also been weighing on some of the biggest losers, like regeneron, down 14% so far this year. the cholesterol drug blocked from the market after a court ruling. mylan with epp pen dropping the price there. that said, you have some winner easy in biotech. vertex pharma, illumina. and some hitting a new high. >> thank you, bertha. >>> meanwhile, a trifecta of highs for the market today. the dow cracking 20k, while the s&p 500 and nasdaq are at record highs, thanks in part to leadership from tech stocks, including apple. eric hippo, managing partner, joins us here at post 9 with the back drop of all that. welcome. thanks for being with us. >> my pleasure. >> so, eb dynamics about to go public, was snatched up by cisco for about twice the expected market valuation. i guess that's not a bad thing. but given there's been a couple of months for the concept of a trump presidency and his policies to sink in, how are you feeling as far as tech investment and the environment for not just ipos but companies that have the prospect of going public? >> i'm feeling very good. i thi

tonight amgen won a big verdict blogging regeneron's drug. there's a lot of competition. is it possible some people could view that -- i'll use a term that i saw on the web, that you cherry picked data points that made the results look better. or is it just such a terrible disease that anything you can do is better than what we have as the current standard of care and that's what we should be focused on? >> our phase two study is a large, well-designed and controlled phase two study of over 250 patients. what we've presented today was a conservative review of all of the study populations looking at the key efficacy end points of progression free survival and overall survival. there was a good consistency. in the overall data, particular lit with regards to progression-free survival. now, overall survival was a secondary end point and an exploratory end point. i mentioned we saw the 50% improvement in overall survival in the stage two patients who had high levels of the sugar. when we actually look at the overall population, we didn't see a benefit. and there's a number of

they give guidance and preannounce so people will being looking at news from them as well as regeneron. >> josh, you mentioned the move in xbi. i made a comment whether it's the run-up and the sell -- it's the run-up ahead of this conference. >> that would be there. something to that. how they will run retail stocks into back to school. there's high expectations going in. it's important to note, xbi is equal weight, so it's basically 40 stocks that are 2.5% each, give or take. it tends to favor the smaller bio ticks more speculative attractive ahead of something like this. but amgen is rock and rolling. bristol-myers, huge turn around. the big stocks in health care, pharma, also participating. so maybe it's more than just the run into the health care conference. >> do you like it? >> yeah, health care is a favorite sector for 2014. it takes all four boxes. >> down last year. >> down last year, helps. >> in terms of strong secular demand story. fundamentals where we see solid earnings and sales growth, how many sectors can you say that for? valuations, one of the only sector trading bel

meg is going to come to us again from the jpmorgan conference with the ceo of regeneron. with sarah. david, back to you. >> thank you very much. >>> when we come back, sarah is sitting down exclusively with the ceo of lululemon. we'll get his take on the state of the consumer, retail and the trump era. we have a lot more ahead. stay with us. when you travel, you want your needs to be understood no matter where you go. you want an experience that feels highly personalized. with watson on the ibm cloud, travel companies like wayblazer can apply cognitive analytics to social data to understand what a destination is really like. and who exactly, it will appeal to. today watson is helping businesses create experiences that revolve around you. because that's what the ibm cloud is built for. >>> welcome back to "squawk on the street." the annual icr consumer conference is happening today in orlando, florida. joining me now, cn nrkcnbc excl is laurent potdevin, the ceo of lululemon. you narrowed your sales and profit forecast to the higher end of the range, which isn't the kind o

. >> now chairman of regeneron people don't talk about that anymore. son by the way is doing a very important project in terms of measuring blood pressure. it would make it so these wearables would finally not have the false positive of blood pressure which is what you need. the j.p. morgan upgrade push of disney was so interesting. i did like a word search. espn is not even in -- it's only tange tangentially mentioned. now we're talking about new theme park rides. new theme park rides. >> i think there are people out there who are going to still be counting subs when it comes to disney and espn. >> you do? >> yes, i do. yes, i do. >> the sub loss is moderated, we should point out. >> it has. >> credit suisse with a chart earlier in the week moderated in '16 from 2% to 3% in '15. so it's getting worse but not as quickly as it was. >> yeah. we'll see. >> the stock is up from 93. >> we're just at the outset though. hulu is yet to introduce their streaming platform, their over-the-top product. google will have one. conceivably from what we're hearing pote

the ruling is a defeat for regeneron and sanofi, which makes a rival drug.ompanies plan to appeal. that's painful. >>> a federal judge has cut in half a jury verdict ordering johnson & johnson to pay more than $1 billion to plaintiffs who say they were injured by the company's pinnacle hip implants. the judge upheld the jury's findings. the implants were defectively designed, but they cited constitutional considerations that limit punitive damages. >> sounds better when you say implant. >> constitutional is a word we don't even have. we don't have a constitution. >> which is one of the problems, i think. >>> and blackstone is reportedly -- you've made some steps in recent months. i like everything about you. >> about him. >> no, i like everything about europe. i'm a little frustrated that you have the country of italy and you can't make an event with your banks and economies and stuff like that. >> i'm not personally to blame for that, you realize. i can't make a go of it. >> i can do a sixth degree of separation where you're at least complicit. greece, gree

new genon energy oh also regeneron also-- bouncing today. --vergence herein incorrectly.genda. factors that may influence the central bank in 2017. this is bloomberg. ♪ oliver: this is "bloomberg markets." the fed unveils the minutes from its december meeting tomorrow. will be an interesting year for the fed in 2017 as a strengthening dollar and the unknown variables of the trump presidency could force janet yellen off the rate hike path. joining us, mike mckee and joe weisenthal. what are we looking for in these minutes beyond rates went up? mike: not a whole lot. we make it some indication of they feel about raising interest rates again and whether or not there was any discussion of what the trump policies would impact -- what the impact of trump policies would be. if we get a lot of stimulus and people are worried about with the going up and fed could be forced to race sooner and faster. suppose we get a trade war. fed isnomy tanks and the forced to be on hold or even look at cutting rates. a lot of uncertainty. ngarlet: a lot of guesstimati going on. you have a new fa